Considerations in developing medical countermeasures against chemical ocular toxicity

David T Yeung; Houmam Araj; Jill R Harper; Gennady E Platoff Jr

doi:10.1016/j.toxlet.2020.09.004

Considerations in developing medical countermeasures against chemical ocular toxicity

Toxicol Lett. 2020 Nov 1:334:1-3. doi: 10.1016/j.toxlet.2020.09.004. Epub 2020 Sep 8.

Authors

David T Yeung¹, Houmam Araj², Jill R Harper³, Gennady E Platoff Jr⁴

Affiliations

¹ Department of Health and Human Services, National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), 5601 Fishers Lane (1G58), Bethesda, MD, 20892, USA. Electronic address: dy70v@nih.gov.
² Department of Health and Human Services, National Eye Institute/National Institutes of Health (NEI/NIH), 6700B Rockledge Dr (Suite 3400), Bethesda, MD, 20817, USA. Electronic address: houmam.araj@nih.gov.
³ Department of Health and Human Services, National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), 31 Center Drive (MSC 2520), Bethesda, MD, 20892, USA. Electronic address: jharper@nih.gov.
⁴ Department of Health and Human Services, National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), 5601 Fishers Lane (1G55), Bethesda, MD, 20892, USA. Electronic address: platoffg@nih.gov.

Abstract

The Chemical Countermeasures Research Program (CCRP) was established in 2006 by the National Institute of Allergy and Infectious Diseases (NIAID/NIH) on behalf of the National Institutes of Health Office of the Director (NIH OD). It is a trans-NIH initiative to expedite the discovery and early development of medical countermeasures (MCMs) that can reduce mortality and serious morbidity during and after large consequence public health emergency involving the deliberate or accidental large-scale release of highly toxic chemicals (HTCs).

Keywords: CCRP; Chemical threats; Medical countermeasures; Ocular toxicity; Vesicants.

Published by Elsevier B.V.

MeSH terms

Disaster Planning / methods*
Eye / drug effects*
Hazardous Substances / toxicity*
Humans
Medical Countermeasures*
National Institute of Allergy and Infectious Diseases (U.S.)
Public Health
Toxic Optic Neuropathy / prevention & control*
United States

Substances

Hazardous Substances

Grants and funding

Z99 AI999999/ImNIH/Intramural NIH HHS/United States